Also found in: Medical.
a1PIHuman Alpha 1-Proteinase Inhibitor
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
8 February 2010 - US-based biopharmaceutical company Talecris Biotherapeutics Inc (NASDAQ: TLCR) announced on Friday that it was granted orphan drug designation by the US Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha(1)-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha(1)-antitrypsin (AAT) deficiency.
The "generic" name of this drug is Alpha 1-Proteinase Inhibitor, or A1PI. It is an "orphan drug" meaning that it was developed under special federal guidelines that encourage research in die treatment of mm diseases.
* Treatment -- with Alpha 1-Proteinase Inhibitor (A1PI) only if a person has AAT deficiency-related emphysema.